Different forms of chronic childhood thrombocytopenic purpura defined by antiplatelet autoantibodies
Related Experiment Videos
P Imbach1, P Tani, W Berchtold
1Central Laboratory Swiss Red Cross, Blood Transfusion Service, Bern.
Insights
Detection of antiplatelet autoantibodies (AAb) can help differentiate childhood chronic thrombocytopenic purpura (TP). High AAb levels in children may indicate a prognosis similar to adults, while lower levels suggest potential spontaneous remission.
Area of Science:
- Immunology
- Hematology
- Pediatrics
Background:
- Chronic thrombocytopenic purpura (TP) in children presents diagnostic challenges.
- Understanding the role of antiplatelet autoantibodies (AAb) is crucial for prognostication.
Purpose of the Study:
- To investigate the utility of detecting antiplatelet autoantibodies (AAb) against glycoproteins IIb/IIIa and Ib/IX.
- To define different forms of chronic thrombocytopenic purpura (TP) in pediatric patients.
Main Methods:
- Analysis of platelet and plasma samples for AAb in children and adults with chronic TP.
- Correlation of AAb detection with clinical data and patient age at diagnosis.
Main Results:
- AAb were detected in a majority of children and adults with ongoing chronic TP.
- Children diagnosed with high AAb levels were older at diagnosis and showed outcomes potentially similar to adults.
- Elevated AAb in children with a history of TP may indicate compensated TP and risk of relapse.
Conclusions:
- AAb detection may aid in classifying childhood chronic TP.
- Age at diagnosis and AAb levels could predict disease course and remission potential in pediatric TP.
- Further longitudinal studies on serial AAb determination are warranted to define TP subgroups.
Abstract:
To determine whether detection of antiplatelet autoantibodies (AAb) to glycoproteins IIb/IIIa and Ib/IX may be useful in defining different forms of chronic thrombocytopenic purpura (TP) in children, we analyzed for AAb the platelet and plasma samples from 36 children with chronic TP (mean duration 4.4 years), from 31 children with normal platelet counts at the time of blood sampling but with chronic TP in the past (mean duration 2.9 years), and from 23 adults with chronic TP; the results were correlated with the clinical data. Antiplatelet autoantibodies were detected in 26 (72.2%) of 36 children with ongoing TP, 15 (48.4%) of 31 children with TP in the past, and 12 (66.7%) of 18 adults with TP. All children with high AAb ratios (greater than 5 times the control mean + 3 SD) were more than 8 years of age at diagnosis (mean age 12.4 years compared with 7.1 years in children with moderate or negative AAb levels; p = 0.003). The results suggest that the outcome for adolescents with high platelet-associated AAb levels may be similar to that of adults, whereas younger children may have a greater chance of spontaneous remission. The children with chronic TP in the past and elevated platelet-associated AAb levels may have a "compensated" TP and therefore may be at risk for relapses. Future studies aimed at serial AAb determination throughout the patients' courses may further define TP subgroups.